Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Total Debt: 2022-2024

Historic Total Debt for Centessa Pharmaceuticals (CNTA) over the last 3 years, with Dec 2024 value amounting to $108.9 million.

  • Centessa Pharmaceuticals' Total Debt rose 45.07% to $109.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $109.8 million, marking a year-over-year increase of 45.07%. This contributed to the annual value of $108.9 million for FY2024, which is 43.91% up from last year.
  • Centessa Pharmaceuticals' Total Debt amounted to $108.9 million in FY2024, which was up 43.91% from $75.7 million recorded in FY2023.
  • In the past 5 years, Centessa Pharmaceuticals' Total Debt registered a high of $108.9 million during FY2024, and its lowest value of $69.8 million during FY2022.
  • In the last 3 years, Centessa Pharmaceuticals' Total Debt had a median value of $75.7 million in 2023 and averaged $84.8 million.
  • Data for Centessa Pharmaceuticals' Total Debt shows a peak YoY surged of 43.91% (in 2024) over the last 5 years.
  • Centessa Pharmaceuticals' Total Debt (Yearly) stood at $69.8 million in 2022, then increased by 8.45% to $75.7 million in 2023, then skyrocketed by 43.91% to $108.9 million in 2024.